Veru Inc. (VERU) Analysis

Over the last 7 days, the United States market has risen by 1.7%, and over the past year, it is up 12%, with earnings forecasted to grow by 15% annually. For investors seeking opportunities beyond well-known stocks, penny stocks can offer intriguing prospects, especially when they possess strong balance sheets and solid fundamentals. Although the term "penny stock" might seem outdated, these smaller or newer companies continue to present valuable growth potential at lower price points.

Hey, $VERU is making news again, and this news could be a game-changer! Veru Inc. ($VERU) just announced positive results from their Phase 2b QUALITY and Maintenance Extension Study for Enobosarm, and it’s very positive ! Here’s the quick rundown: Enobosarm crushed it: Showed a 71% reduction in lean mass loss when combined with semaglutide (Wegovy) for weight loss. The 3mg dose? >99% reduction in lean mass loss! Post-semaglutide benefits: Significantly reduced body weight regain, prevented ...

> “Not financial advice. Just trying to print tendies off your GLP-1 side effects.” --- TL;DR: $VERU owns enobosarm, a selective androgen receptor modulator (SARM) with dual market potential: ✅ Body recomposition / weight maintenance after semaglutide (Ozempic, Wegovy) ✅ HR+/HER2- metastatic breast cancer with FDA Fast Track status In a post-GLP-1 world, patients are regaining fat after stopping Ozempic-style drugs. Enobosarm reverses that trend: 🔥 Cuts fat regain in half 💪 100% lean muscle ...